HomeCompareKTRA vs MRK

KTRA vs MRK: Dividend Comparison 2026

KTRA yields 928.51% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KTRA wins by $9.224768444729638e+22M in total portfolio value
10 years
KTRA
KTRA
● Live price
928.51%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$9.224768444729638e+22M
Annual income
$92,228,602,655,528,430,000,000,000,000.00
Full KTRA calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — KTRA vs MRK

📍 KTRA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKTRAMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KTRA + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KTRA pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KTRA
Annual income on $10K today (after 15% tax)
$78,922.93/yr
After 10yr DRIP, annual income (after tax)
$78,394,312,257,199,170,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, KTRA beats the other by $78,394,312,257,199,170,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KTRA + MRK for your $10,000?

KTRA: 50%MRK: 50%
100% MRK50/50100% KTRA
Portfolio after 10yr
$4.612384222364819e+22M
Annual income
$46,114,301,327,764,220,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

KTRA
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Altman Z
-7.7
Piotroski
1/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KTRA buys
0
MRK buys
0
No recent congressional trades found for KTRA or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKTRAMRK
Forward yield928.51%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$9.224768444729638e+22M$56.8K
Annual income after 10y$92,228,602,655,528,430,000,000,000,000.00$9,798.13
Total dividends collected$9.22464356544689e+22M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: KTRA vs MRK ($10,000, DRIP)

YearKTRA PortfolioKTRA Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$196,401$185,701.02$11,206$366.19+$185.2KKTRA
2$7,027,321$6,817,172.01$12,650$502.35+$7.01MKTRA
3$463,447,509$455,928,275.47$14,407$694.19+$463.43MKTRA
4$56,698,112,446$56,202,223,611.72$16,585$967.82+$56698.10MKTRA
5$12,912,579,631,755$12,851,912,651,437.11$19,342$1,363.89+$12912579.61MKTRA
6$5,484,711,654,366,623$5,470,895,194,160,645.00$22,913$1,947.19+$5484711654.34MKTRA
7$4,349,424,397,994,440,700$4,343,555,756,524,268,500.00$27,662$2,823.89+$4349424397994.41MKTRA
8$6,442,930,094,194,810,000,000$6,438,276,210,088,955,000,000.00$34,159$4,173.35+$6442930094194810.00MKTRA
9$17,833,450,250,405,050,000,000,000$17,826,556,315,204,260,000,000,000.00$43,337$6,308.80+$17833450250405050368.00MKTRA
10$92,247,684,447,296,380,000,000,000,000$92,228,602,655,528,430,000,000,000,000.00$56,776$9,798.13+$9.224768444729638e+22MKTRA

KTRA vs MRK: Complete Analysis 2026

KTRAStock

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

Full KTRA Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this KTRA vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KTRA vs SCHDKTRA vs JEPIKTRA vs OKTRA vs KOKTRA vs MAINKTRA vs JNJKTRA vs ABBVKTRA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.